New York, Jan 9, 2026, 15:54 EST — Regular session
- iRhythm Technologies shares fell about 4% in afternoon trading, lagging a broader U.S. market rise.
- Investors digested a softer U.S. jobs report and the shifting outlook for interest rates.
- Next catalyst: iRhythm is scheduled to present at the J.P. Morgan Healthcare Conference on Jan. 12.
Shares of iRhythm Technologies (IRTC.O) fell 3.9% to $181.95 on Friday, after swinging between $190.16 and $179.61 in the session. The stock ended Thursday at $189.25.
The drop left iRhythm behind a broader advance in U.S. equities, with S&P 500 and Nasdaq-tracking funds up about 0.8% and 1.1%, respectively. That gap matters because iRhythm trades like a growth stock — sensitive to rate moves and risk appetite — and those currents can swamp stock-specific news for stretches.
A Labor Department report showed nonfarm payrolls — a broad count of jobs outside agriculture — rose 50,000 in December, below the 60,000 forecast by economists polled by Reuters, while the unemployment rate dipped to 4.4%. “All roads lead to the unemployment rate … it should douse the Fed’s recent urgency,” said Olu Sonola, head of U.S. economic research at Fitch Ratings; economists also expect the Federal Reserve to keep rates unchanged at its Jan. 27-28 meeting. 1
For iRhythm investors, the next clean read comes quickly. The company said its management is scheduled to present at the J.P. Morgan Healthcare Conference on Jan. 12 at 11:15 a.m. Eastern, with a webcast available to investors.
Beyond the macro, the setup is familiar: a widely followed healthcare conference where investors press for updated demand signals, pricing and any early hints on 2026 priorities. With the stock already showing big intraday swings, the bar for “new” information can be low.
iRhythm designs and sells the Zio patch-based remote ECG monitoring system — ECG is an electrocardiogram — which can record heart signals continuously for up to 14 days, alongside software that helps analyze the data. The company reported a net loss of $113.3 million in 2024, according to LSEG data compiled by Reuters. 2
But the downside case does not disappear just because rates cooperate. Reimbursement and payer behavior can change quickly in medical monitoring, and competition from larger device makers can squeeze pricing — risks that tend to show up first in volume trends and margins.
Investors’ next checkpoint is Monday’s J.P. Morgan conference appearance, where iRhythm’s message and tone often drive near-term positioning.
